Repatha cuts first major cardiovascular event risk by 29% in high-risk diabetes patients, new trial data show

New Phase 3 VESALIUS-CV trial data reveal that Repatha (evolocumab), added to statins, reduces the risk of first major cardiovascular events by 29% in patients with high-risk diabetes and elevated LDL cholesterol. The study involved 6,002 patients without prior heart attack or stroke and showed significant benefits regardless of concurrent diabetes therapies. These findings highlight the importance of aggressive LDL-C management in high-risk diabetes to prevent heart attacks and strokes. Amgen also presented real-world evidence emphasizing the need for sustained treatment adherence in obesity and diabetes care to maximize therapy benefits.